Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Nish Patel

Interventional Cardiology Miami, FL Medical Doctor

NPI 1801107867 CMS profile 585422

8950 N Kendall Dr Ste 600W, Miami, FL 33176

Open in the dashboard

General payments

$149,145

575 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$76,432 paid to institutions, not to them · program years 2024–2025

Through program year 2025, Nish Patel of Miami, FL is reported in the CMS Open Payments database as having received $149,145 across 575 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $76,432 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 94th percentile of Interventional Cardiology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $40,637 111
2024 General $57,030 104
2023 General $7,013 58
2022 General $23,855 73
2021 General $10,367 93
2020 General $3,555 50
2019 General $6,688 86

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Nish Patel
  • Interventional Cardiology median
  • Middle half of Interventional Cardiology
  • National median

In program year 2025, general payments to Nish Patel were reported at $40,637. Among 6,173 Interventional Cardiology profiles paid that year, the median was $1,092 and the middle half received between $366 and $3,019.

Show as a table
Year Nish Patel Interventional Cardiology median Middle half National median
2019 $6,688 $1,097 $329–$3,048 $163
2020 $3,555 $473 $161–$1,480 $114
2021 $10,367 $677 $233–$1,827 $132
2022 $23,855 $978 $333–$2,724 $149
2023 $7,013 $1,136 $382–$2,986 $160
2024 $57,030 $1,181 $395–$3,326 $164
2025 $40,637 $1,092 $366–$3,019 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Edwards Lifesciences Corporation $77,870 195 payments
  2. Medtronic, Inc. $26,597 52 payments
  3. W. L. Gore & Associates, Inc. $21,671 29 payments
  4. Abbott Laboratories $11,620 99 payments
  5. Boston Scientific Corporation $2,489 24 payments
  6. Philips Electronics North America Corporation $2,179 18 payments
  7. Medtronic Vascular, Inc. $1,822 20 payments
  8. Cardiva Medical, Inc. $587 6 payments
  9. ZOLL Circulation Inc $425 3 payments
  10. Abiomed $421 14 payments
  11. Other $3,463 115 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Consulting Fee $74,683 26 payments
  2. Travel and Lodging $27,304 106 payments
  3. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $24,963 16 payments
  4. Food and Beverage $21,507 423 payments
  5. Education $689 4 payments
Products named General payments · program years 2019–2025
  1. EDWARDS SAPIEN 3 TRANSCATHETER HEART VALVE (THV) $39,569 75 payments
  2. COREVALVE EVOLUT R $22,211 39 payments
  3. Product in Development $20,924 25 payments
  4. Edwards SAPIEN 3 Ultra Transcatheter Heart Valve $14,229 10 payments
  5. SAPIEN 3 Ultra RESILIA $5,734 15 payments
  6. CoreValve Evolut Transcatheter Valve Systems $4,152 9 payments
  7. MITRACLIP $2,421 20 payments
  8. NAVITOR $2,252 5 payments
  9. CoreValve Evolut Transcatheter Valve Systems $1,822 20 payments
  10. Omnilink Elite vascular stent system $1,556 11 payments
  11. Other $17,857 278 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 8 drugs

Part D claims

176

Median for Interventional Cardiology: 2,236

Drug cost

$44,916

Median for Interventional Cardiology: $380,412

Branded share of claims

34.1%

Median for Interventional Cardiology: 27.8%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Entresto Sacubitril/Valsartan Brand 19 $29,447
Brilinta Ticagrelor Brand 18 $14,364
Metoprolol Succinate Generic 50 $475
Clopidogrel Clopidogrel Bisulfate Brand 23 $239
Losartan Potassium Generic 19 $114
Amlodipine Besylate Generic 13 $110
Atorvastatin Calcium Generic 22 $106
Furosemide Generic 12 $62

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 4,694 Part D prescribers listed as Interventional Cardiology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 43 billing codes

Paid by Medicare

$101,263

Medicare's payments for the services billed

Medicare patients

181

Average age 78

Services billed

602

71 women, 110 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Ischemic heart disease 75%
Heart failure 60%
Diabetes 52%
Chronic kidney disease 52%
Arthritis 52%
Atrial fibrillation 49%
COPD 33%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

1 product · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
CAMZYOS
  • E.R. Squibb & Sons, L.L.C. $34
$34 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

575 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Interventional Cardiology in Florida

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record